The FDA approved sevabertinib in first-line HER2-mutant lung cancer, durvalumab plus tarlatamab boosted survival in ES-SCLC, and more.
Related to this article
The positive CHMP opinion for teclistamab in second- and later-line relapsed/refractory multiple myeloma is supported by MajesTEC-9 data.
CHMP offerred a positive opinion supporting extension of melflufen to third-line, lenalidomide-refractory multiple myeloma.
The latest updates to the NCCN Guidelines for multiple myeloma expand minimal residual disease testing guidance.
Prophylactic tocilizumab before step-up dosing lowered CRS rates approximately 5-fold with teclistamab and talquetamab in relapsed/refractory myeloma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
Zipalertinib + Chemotherapy Extends PFS by 6 Months in Frontline EGFR Exon 20 Insertion–Positive NSCLC
2
FDA Grants Breakthrough Therapy Designation to First-Line Daraxonrasib Plus Chemo in mPDAC
3
Updated NCCN Guidelines Feature Additional MRD Recommendations in Multiple Myeloma
4
EU Approval Reccomended by CHMP for Senaparib in First-Line Advanced Ovarian Cancer
5